A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record

Thrombosis and Haemostasis

Volumn 113, Issue 4, 2015, Pages 772-781

  Karnes, Jason H ^a   Cronin, Robert M ^a   Rollin, Jerome ^b   Teumer, Alexander ^c   Pouplard, Claire ^b   Shaffer, Christian M ^a   Blanquicett, Carmelo ^a   Bowton, Erica A ^a   Cowan, James D ^a   Mosley, Jonathan D ^a   van Driest, Sara L ^a   Weeke, Peter E ^a,d   Wells, Quinn S ^a   Bakchoul, Tamam ^c   Denny, Joshua C ^a   Greinacher, Andreas ^c   Gruel, Yves ^b   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Heparins; Pharamacogenetics; Thrombocytopenia

Indexed keywords

HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; ANTIBODY; ANTICOAGULANT AGENT; G PROTEIN COUPLED RECEPTOR; GPR65 PROTEIN, HUMAN; HLA DR ANTIGEN; THROMBOCYTE FACTOR 4;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CHROMOSOME 14; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; AGED; BIOBANK; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; ELECTRONIC HEALTH RECORD; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; MIDDLE AGED; ODDS RATIO; PHENOTYPE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; ANTIBODIES; ANTICOAGULANTS; BIOLOGICAL SPECIMEN BANKS; CHI-SQUARE DISTRIBUTION; ELECTRONIC HEALTH RECORDS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEPARIN; HLA-DR ALPHA-CHAINS; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; PLATELET FACTOR 4; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, G-PROTEIN-COUPLED; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84928656687     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-08-0670     Document Type: Article

References (46)

1. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
2. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101: 2955-2959.
3. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135.
4. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J 2005; 3: 14.
5. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a metaanalysis. Blood 2005; 106: 2710-2715.
6. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparininduced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e495S-530S.
7. Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528-540.
8. Cuker A. Heparin-induced thrombocytopenia: present and future. J Thromb Thrombolysis 2011; 31: 353-366.
9. Pamela S, Anna Maria L, Elena D, et al. Heparin-induced thrombocytopenia: the role of platelets genetic polymorphisms. Platelets 2013; 24: 362-368.
10. Rollin J, Pouplard C, Leroux D, et al. Impact of polymorphisms affecting the ACP1 gene on levels of antibodies against platelet factor 4-heparin complexes. J Thromb Haemost 2013; 11: 1609-1611.
11. Rollin J, Pouplard C, Gratacap MP, et al. Polymorphisms of protein tyrosine phosphatase CD148 influence FcgammaRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood 2012; 120: 1309-1316.
12. Pouplard C, Cornillet-Lefebvre P, Attaoua R, et al. Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia. Thromb Res 2012; 129: 465-469.
13. Gruel Y, Pouplard C, Lasne D, et al. The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 2004; 104: 2791-2793.
14. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B.*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819.
15. Mallal S, Phillips E, Carosi G, et al. HLA-B.*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
16. Phillips EJ, Mallal SA. HLA-B.*1502 screening and toxic effects of carbamazepine. N Engl J Med 2011; 365: 672; author reply 673.
17. Selleng S, Greinacher A, Ittermann T, et al. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Am Heart J 2009; 158: e15.
18. Greinacher A, Kohlmann T, Strobel U, et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970-4976.
19. Warkentin TE, Sheppard JA, Moore JC, et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963-4969.
20. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
21. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale deidentified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008; 84: 362-369.
22. Denny JC, Spickard A, 3rd, Johnson KB, et al. Evaluation of a method to identify and categorize section headers in clinical documents. J Am Med Inform Assoc 2009; 16: 806-815.
23. Denny JC, Miller RA, Waitman LR, et al. Identifying QT prolongation from ECG impressions using a general-purpose Natural Language Processor. Int J Med Inform 2009; 78: S34-42.
24. Cuker A, Gimotty PA, Crowther MA, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and metaanalysis. Blood 2012; 120: 4160-4167.
25. Volzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol 2011; 40: 294-307.
26. Greinacher A, Holtfreter B, Krauel K, et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118: 1395-1401.
27. Ludemann J, Piek M, Wood WG, et al. [Methods for quality assurance of medical examination in epidemiological field studies: the "Study of Health in Pomerania" (SHIP)]. Gesundheitswesen 2000; 62: 234-243.
28. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
29. Althaus K, Strobel U, Warkentin TE, et al. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res 2011; 128: 256-260.
30. Zuvich RL, Armstrong LL, Bielinski SJ, et al. Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality. Genet Epidemiol 2011; 35: 887-898.
31. Howie B, Fuchsberger C, Stephens M, et al. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955-959.
32. Abecasis GR, Altshuler D, Auton A, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
33. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
34. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
35. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
36. Jia X, Han B, Onengut-Gumuscu S, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013; 8: e64683.
37. Choi JW, Lee SY, Choi Y. Identification of a putative G protein-coupled receptor induced during activation-induced apoptosis of T cells. Cell Immunol 1996; 168: 78-84.
38. Onozawa Y, Fujita Y, Kuwabara H, et al. Activation of T cell death-associated gene 8 regulates the cytokine production of T cells and macrophages in vitro. Eur J Pharmacol 2012; 683: 325-331.
39. Onozawa Y, Komai T, Oda T. Activation of T cell death-associated gene 8 attenuates inflammation by negatively regulating the function of inflammatory cells. Eur J Pharmacol 2011; 654: 315-319.
40. Bacsi S, De Palma R, Visentin GP, et al. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/ thrombosis. Blood 1999; 94: 208-215.
41. Fleischer J, Grage-Griebenow E, Kasper B, et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 2002; 169: 770-777.
42. Suvarna S, Rauova L, McCracken EK, et al. PF4/heparin complexes are T celldependent antigens. Blood 2005; 106: 929-931.
43. Scheuerer B, Ernst M, Durrbaum-Landmann I, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158-1166.
44. Paparella D, Micelli M, Favoino B, et al. Anti-heparin-platelet factor 4 antibodies after cardiopulmonary bypass: role of HLA expression. Haematologica 2001; 86: 326-327.
45. Harris K, Nguyen P, Van Cott EM. Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. Am J Clin Pathol 2008; 129: 282-286.
46. Carlsson LE, Lubenow N, Blumentritt C, et al. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 2003; 13: 253-258.